Global Access Program - Hepatitis

Hepatitis B and C are among the most common viral infections in the world. At least 263 million worldwide in 2017 – are carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.^1,2

95% of people living with viral

hepatitis do not know.

In 2016, the World Health Assembly adopted WHO’s first

“Global Health Sector Strategy on viral hepatitis,”

with elimination as its overarching vision.

Globally, 263 million

persons are infected

Vision, goal and targets

VISION

A world where viral hepatitis transmission is halted

and everyone living with viral hepatitis has access to

safe, affordable and effective prevention, care and

treatment services.

GOAL

Eliminate viral hepatitis as a major public health

threat by 2030.

TARGETS

Between 6 and 10 million infections are

reduced to less than 1 million by 2030;

1.4 million deaths reduced to less than 500 000 by 2030.

72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds

Roche committed to the elimination of hepatitis

To advance global efforts and eliminate viral hepatitis, Roche is committed

to this motivational program underscoring our ongoing efforts to provide

life-saving diagnostics, and supports governments aiming to cure people

of hepatitis.

Roche is a leader in viral load testing and is dedicated to enabling

improved patient management by delivering innovative, high-quality

diagnostic solutions where they are needed most.